Please login to the form below
Jazz Pharma
This page shows the latest Jazz Pharma news and features for those working in and with pharma, biotech and healthcare.
Jazz Pharma’s SCLC drug fails to meet primary endpoint in combo trial
Drug combination failed to improve overall survival rate. Jazz Pharmaceuticals and PharmaMar have revealed that their small cell lung cancer (SCLC) therapy lurbinectedin has failed to meet the primary endpoint in ... Jazz licensed lurbinectedin from
Latest news
-
Redx Pharma links up with Jazz Pharmaceuticals to develop targeted cancer drugs
UK-based Redx Pharma has signed a research collaboration with Jazz Pharmaceuticals focused on discovering and developing drug candidates for two new cancer targets. ... We look forward to collaborating with Jazz on new targeted therapies for patients who
-
Syncona start-up Quell Therapeutics appoints chief exec
Iain McGill. Iain McGill has been recruited from his role as senior vice president Europe and Rest of World for Jazz Pharmaceuticals, the specialist pharma company, best known in Europe for ... He was part of the management team which
-
Daily Brief: Jazz Pharma and Ultragenyx approvals, Autonomous AI in retinopathy
The latest from pharma, biotech and healthcare. Jazz Pharma gains EU approval for niche AML treatment. ... or AML with myelodysplasia-related changes,” said Daniel Swisher, president and chief operating officer at Jazz Pharmaceuticals.
-
Jazz Pharma bags FDA approval for rare disease drug
The US FDA has given the green light for Jazz Pharma's Defitelio, adding another product to the company's stable of rare disease therapies. ... Jazz acquired Defitelio as part of its $1bn purchase of Italy's Gentium in 2013.
-
Baxter buoys cancer presence with $900m Oncaspar deal
disease therapy sector, with suggestions Shire or Jazz Pharma may be interested in the unit.
Redx Pharma links up with Jazz Pharmaceuticals to develop targeted cancer drugs
Syncona start-up Quell Therapeutics appoints chief exec
Daily Brief: Jazz Pharma and Ultragenyx approvals, Autonomous AI in retinopathy
Jazz Pharma bags FDA approval for rare disease drug
Baxter buoys cancer presence with $900m Oncaspar deal
More from news
Approximately 1 fully matching, plus 10 partially matching documents found.
Latest Intelligence
-
Deal Watch July 2016
$11m. Servier. Sorrento. $821m. $28m. Jazz Pharma. Pfenex. $181m. $15m. ONO Pharma. ... Sprint BioScience/ Petre Pharma. PIP4K2a inhibitor programme. Licence. 240. Pfenex/ Jazz Pharmaceuticals.
-
Pharma deals in March 2015
The other deal of interest is the re-emergence of EUSA Pharma with products acquired from Jazz Pharmaceuticals. ... investor, Essex Woodlands, has bought back products worth $27m and the EUSA Pharma name from Jazz for an undisclosed amount.
Deal Watch July 2016
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
EUSA Pharma appoints Lee Morley as its new chief executive
EUSA's new CEO Morley comes to the company from Jazz, where he was vice president, head of commercial for Europe and International Markets, with responsibility for the original EUSA Pharma ... business. Prior to his time with Jazz, and before that the pre
-
EUSA founder joins Oxford BioTherapeutics as chairman
This company was later sold to Jazz Pharma in 2012 for $700m. ... Prior to founding EUSA in 2005, Morton founded Zeneus Pharma in 2003, before selling the company to Cephalon for $360m.
EUSA Pharma appoints Lee Morley as its new chief executive
EUSA founder joins Oxford BioTherapeutics as chairman
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Iguazu
MSD. Sanofi Genzyme. Roche. Merck. Daiichi-Sankyo. Jazz Pharmaceuticals. Gedeon Richter. EUSA Pharma. ... Philip Higgins. Jazz Pharmaceuticals. 0118 3913 664. Address:. Flagstaff House. 14 High Street, Twyford.
Iguazu
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
-
Publications Director
-
Competitive Salary
-
Account Manager
-
Competitive Salary
- Senior & Principal Medical Writer
-
Competitive Salary Offered
-
Senior Account Executive
-
Competitive Salary
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
-
Account Management
-
Competitive Salary Offered
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
-
Medical Editor
-
Competitive Salary
-
Senior Medical Writer
-
Competitive Salary
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
-
Associate Account Director
-
Competitive Salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Positive results for GSK/CureVac’s COVID-19 vaccine
- Merck & Co reveals plans for women’s health spinoff Organon
- Biogen and Capsigen to collaborate on gene therapies
- New court filing alleges Sanofi destroyed emails relating to Zantac recall
- Single dose of COVID-19 vaccines ‘significantly’ reduces infections
- FDA approves Apellis’ Empaveli for rare blood disease
- Sanofi, GSK’s COVID-19 vaccine generates strong immune responses across all age groups
- BMS builds case for cardiovascular drug mavacamten with new analysis
- Biogen and Envisagenics to advance RNA splicing research for CNS diseases
- Mastering commercial launch excellence in a human-centric, hybrid world
- Research Partnership’s MedTech Division appoints two Directors
No results were found
PMHub
Porterhouse Medical Group
The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...
Latest intelligence
- How innovating study sites can improve patient recruitment efficiency
- There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
- 6 reasons patients drop out of clinical trials and 6 ways to fix it
- If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
